BTOG Guidance & Responses
Member Login
Sign Up For Free

Encorafenib plus binimetinib as an option to treat BRAF V600E mutation-positive advanced NSCLC

BTOG wishes to inform members of a new NICE release that has been published today.

 

NICE has recommended encorafenib plus binimetinib as an option to treat BRAF V600E mutation-positive advanced non-small-cell lung cancer (NSCLC) in adults, only if it is used at first line, and the company provides them according to the commercial arrangements.  This recommendation is not intended to affect treatment with encorafenib plus binimetinib that was started in the NHS before this guidance was published. People having treatment outside this recommendation may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS healthcare professional consider it appropriate to stop.

 

For full details and the documents, please see the NICE website:

https://www.nice.org.uk/guidance/gid-ta11140/documents/674

Other News from NICE

New guidance recommends Nivolumab to treat resectable NSCLC

BTOG wishes to inform members of a new NICE release that has been published today for nivolumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer.   NICE has recommended nivolumab...

Lorlatinib update

BTOG wishes to inform members of a new NICE release that has been published today. NICE has recommended Lorlatinib as an option for ALK-positive advanced non-small-cell lung cancer in adults who have not had an ALK inhibitor. There is a commercial access agreement for...

Durvalumab update

BTOG wishes to inform members of a new NICE release that has been published today.NICE has recommended Durvalumab, within its marketing authorisation, as an option to treat limited-stage small-cell lung cancer that has not progressed after platinum-based...

Osimertinib update

BTOG can confirm that NICE has released draft guidance as follows: Osimertinib should not be used for the maintenance treatment of locally advanced (stage 3) unresectable non-small cell lung cancer (NSCLC) in adults when the tumours have epidermal growth factor...